Business, energy, technology, markets and global industry news from Business News Today

Study 306

PharmaDeviceNews Study 306
Veradermics’ Study 207 results could offer early insight into VDPHL01’s efficacy, dose response and safety in women with pattern hair loss. Representative image.
Pharma & Biotech

What Veradermics’ latest oral minoxidil data reveal about long-term hair growth

Veradermics reports sustained VDPHL01 hair growth at 12 months. See what the results mean for safety, FDA review and commercial potential.

Read More
Editorial infographic showing Veradermics’ Phase 3 VDPHL01 hair growth study in 536 men, with hair follicle imagery, a clinical trial document, and references to efficacy, safety, and FDA review.
Pharma & Biotech

What the Veradermics Phase 3 results mean for oral minoxidil treatment

Veradermics reports strong Phase 3 VDPHL01 hair growth results in 536 men. Efficacy is encouraging, but safety and FDA review remain crucial.

Read More
Veradermics’ Study 207 results could offer early insight into VDPHL01’s efficacy, dose response and safety in women with pattern hair loss. Representative image.
Pharma & Biotech

Can VDPHL01 carry its male-trial momentum into women? Veradermics is about to show the data

See why Veradermics’ Study 207 female data could shape VDPHL01 dose selection, safety expectations and its Phase 3 clinical strategy.

Read More